Supply Chain Woes: Full Track-and-Trace Anti-Counterfeiting Not Feasible, Pharma Says
This article was originally published in PharmAsia News
Executive Summary
The pharmaceutical industry is telling U.S. FDA that a full track-and-trace approach for following drugs through the supply chain is not the best way of dealing with the growing counterfeit problem. In the meantime, industry is devising a number of different approaches